General information about company |
|||
|---|---|---|---|
| Scrip Code | 509079 | ||
| NSE Symbol | GUFICBIO | ||
| MSEI Symbol | NOTLISTED | ||
| ISIN | INE742B01025 | ||
| Name of company | GUFIC BIOSCIENCES LIMITED | ||
| Type of company | Main Board | ||
| Class of security | Equity | ||
| Date of start of financial year | 01-Apr-2025 | ||
| Date of end of financial year | 31-Mar-2026 | ||
| Date of board meeting when results were approved | 13-Aug-2025 | ||
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 07-Aug-2025 | ||
| Description of presentation currency | INR (in Actuals) | ||
| Reporting Type | Quarterly | ||
| Reporting Quarter | First quarter | ||
| Nature of report standalone or consolidated | Consolidated | ||
| Whether results are audited or unaudited for the quarter ended | Unaudited | ||
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | |||
| Segment Reporting | Single segment | ||
| Description of single segment | The Company's business activity falls within a single operating segment i.e. Pharmaceuticals | ||
| Start date and time of board meeting | 13-Aug-2025 16:30:00 | ||
| End date and time of board meeting | 13-Aug-2025 18:30:00 | ||
| Whether cash flow statement is applicable on company | |||
| Type of cash flow statement | |||
| Declaration of unmodified opinion or statement on impact of audit qualification | Not applicable | ||
Financial Results Ind-AS |
|||
|---|---|---|---|
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
| A | Date of start of reporting period | 01-Apr-2025 | |
| B | Date of end of reporting period | 30-Jun-2025 | |
| C | Whether results are audited or unaudited | Unaudited | |
| D | Nature of report standalone or consolidated | Consolidated | |
| Part I | Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column. | ||
| 1 | Income | ||
| Revenue from operations | 2237225000 | ||
| Other income | 9252000 | ||
| Total income | 2246477000 | ||
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 885158000 | |
| (b) | Purchases of stock-in-trade | 142682000 | |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | -20127000 | |
| (d) | Employee benefit expense | 359968000 | |
| (e) | Finance costs | 92336000 | |
| (f) | Depreciation, depletion and amortisation expense | 77189000 | |
| (f) | Other Expenses | ||
| 1 | Other Expenses | 536530000 | 536530000 |
| Total other expenses | 536530000 | ||
| Total expenses | 2073736000 | ||
| 3 | Total profit before exceptional items and tax | 172741000 | |
| 4 | Exceptional items | 0 | |
| 5 | Total profit before tax | 172741000 | |
| 6 | Tax expense | ||
| 7 | Current tax | 22200000 | |
| 8 | Deferred tax | 19837000 | |
| 9 | Total tax expenses | 42037000 | |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0 | |
| 11 | Net Profit Loss for the period from continuing operations | 130704000 | |
| 12 | Profit (loss) from discontinued operations before tax | 0 | |
| 13 | Tax expense of discontinued operations | 0 | |
| 14 | Net profit (loss) from discontinued operation after tax | 0 | |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0 | |
| 16 | Total profit (loss) for period | 130704000 | |
| 17 | Other comprehensive income net of taxes | 0 | |
| 18 | Total Comprehensive Income for the period | 130704000 | |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | 0 | ||
| Total profit or loss, attributable to non-controlling interests | 0 | ||
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | 0 | ||
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | 0 | ||
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 100278000 | ||
| Face value of equity share capital | 1 | ||
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | ||
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 1.3 | ||
| Diluted earnings (loss) per share from continuing operations | 1.3 | ||
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | ||
| Diluted earnings (loss) per share from discontinued operations | 0 | ||
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 1.3 | ||
| Diluted earnings (loss) per share from continuing and discontinued operations | 1.3 | ||
| 24 | Debt equity ratio | 0 | |
| 25 | Debt service coverage ratio | 0 | |
| 26 | Interest service coverage ratio | 0 | |
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
Disclosure of notes on financial results |
|||
|---|---|---|---|
| Textual Information(1) | 1. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards), Rules, 2015 (Ind AS) as amended, prescribed under section 133 of Companies Act, 2013, read with rules issued thereunder. n n2. The above results for the quarter ended June 30, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 13, 2025. The Statutory Auditors have carried out limited review of the results for quarter ended June 30, 2025. n n3. The Company's business activity falls within a single operating segment i.e. Pharmaceuticals. n n4. The Consolidated Financial Results for the quarter and financial year ended June 30, 2025, have been prepared by the Company considering the financials of its wholly owned subsidiaries, Gufic UK Limited and Veira Life FZE, and its subsidiary, Gufic Prime Private Limited. As of June 30, 2025, the Company has not made any investment in Gufic Ireland Limited (“GIL”), incorporated in 2023 with the intention of becoming a wholly owned subsidiary, nor has GIL commenced its business operations; hence, consolidation of its accounts with those of the Company was not required. n n5. The equity shares and basic/diluted earnings per share has been presented in accordance with Ind AS - 33-Earning per share. n n6. The figures for the quarter ended March 31, 2025 are balancing figures between audited figures in respect of the full financial year and the unaudited published year-to -date figures up to the third quarter ended December 31, 2024 which were subjected to limited review. n n7. Previous year/quarters figures have been regrouped/reclassified, wherever necessary. | ||
Remarks |
|
|---|---|
| Debt equity ratio | |
| Debt service coverage ratio | |
| Interest service coverage ratio | |
Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results |
|||||||
|---|---|---|---|---|---|---|---|
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
| Date of start of reporting period | 01-Apr-2025 | ||||||
| Date of end of reporting period | 30-Jun-2025 | ||||||
| Whether accounts are audited or unaudited | Unaudited | ||||||
| Nature of report standalone or consolidated | Consolidated | ||||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| Total Segment Revenue | |||||||
| Less: Inter segment revenue | |||||||
| Revenue from operations | |||||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| Total Profit before tax | |||||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | |||||||
| Profit before tax | |||||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| Total Segment Asset | |||||||
| Un-allocable Assets | null | null | |||||
| Net Segment Asset | null | null | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| Total Segment Liabilities | |||||||
| Un-allocable Liabilities | null | null | |||||
| Net Segment Liabilities | null | null | |||||
| Disclosure of notes on segments | |||||||
Other Comprehensive Income |
|||
|---|---|---|---|
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
| A | Date of start of reporting period | 01-Apr-2025 | |
| B | Date of end of reporting period | 30-Jun-2025 | |
| C | Whether results are audited or unaudited | Unaudited | |
| D | Nature of report standalone or consolidated | Consolidated | |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| Total Amount of items that will not be reclassified to profit and loss | |||
| 2 | Income tax relating to items that will not be reclassified to profit or loss | 0 | |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| Total Amount of items that will be reclassified to profit and loss | |||
| 4 | Income tax relating to items that will be reclassified to profit or loss | 0 | |
| 5 | Total Other comprehensive income | 0 | |